Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer. In November 2025, Abbott Laboratories agreed to acquire Exact Sciences in a deal worth roughly $21 billion.
Exact Sciences has received investment from 2 venture capital firms.
Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers.
Exact Sciences has received investment from Domain Associates, OrbiMed Advisors. These venture capital firms and investors provide both capital and strategic support.
Exact Sciences operates in the DevTools sector. Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers.
